Rhumbline Advisers Sells 74 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Rhumbline Advisers lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 5.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,386 shares of the biotechnology company’s stock after selling 74 shares during the quarter. Rhumbline Advisers’ holdings in Ascendis Pharma A/S were worth $216,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. grew its holdings in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 328 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $203,000. Proficio Capital Partners LLC purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at approximately $1,725,000. Jones Financial Companies Lllp raised its position in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares during the last quarter. Finally, Assetmark Inc. raised its position in Ascendis Pharma A/S by 32.9% during the 4th quarter. Assetmark Inc. now owns 2,942 shares of the biotechnology company’s stock worth $405,000 after buying an additional 728 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $173.00 on Thursday. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company has a market cap of $10.58 billion, a PE ratio of -27.55 and a beta of 0.37. The business has a 50-day simple moving average of $166.12 and a 200-day simple moving average of $150.23.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Royal Bank Of Canada lifted their target price on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a “buy” rating in a research note on Monday, June 9th. Morgan Stanley raised shares of Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $180.00 to $250.00 in a research report on Monday, May 5th. Oppenheimer reissued an “outperform” rating and set a $224.00 price target (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Finally, Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $220.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.